Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Files Combination Drug for Parkinson’s Disease in Japan
June 28, 2013
- Bayer Yakuhin to Shift Resources to Innovative New Drugs: President Brunn
June 28, 2013
- Reasons for Doctors’ Reluctance to Generic Name Prescribing is Time and Effort: CareNet Survey
June 28, 2013
- Tsumura Reports Record Profits through Intensified MR Activities to Educate Doctors about Kampo Medicine
June 28, 2013
- Astellas Begins Global PIII Study of Cytomegalovirus Vaccine
June 27, 2013
- Shionogi Establishes New Chinese Subsidiary
June 27, 2013
- Astellas, Cytokinetics Agree to Develop, Commercialize Skeletal Muscle Activators
June 27, 2013
- Takeda Files BLA for CD, UC Treatment in US
June 27, 2013
- Eisai Launches Aricept Dry Syrup
June 26, 2013
- Eisai to Suspend Sales of Future Mainstay Antiepileptic Drug in Germany
June 26, 2013
- Success in Emerging Markets Key for Drug Makers’ Growth: IMS Japan Senior Principal
June 26, 2013
- Myelofibrosis Treatment Jakavi Reduced Risk of Death by 52% in 3-Year Follow-up Study: Novartis AG
June 26, 2013
- Anticancer Agent Xtandi Receives Approval Also in Europe: Astellas
June 26, 2013
- Filgrastim Biosimilars: Overseas Track Record vs. “Purely Made-in-Japan” Label
June 25, 2013
- Novartis AG Probing 10-Plus Years of Documents, Emails over Diovan Papers
June 25, 2013
- Taiho to Launch New Formulation TS-1, World’s 1st Anticancer OD Tablets
June 25, 2013
- UMN, API, Yakult Officially Agree on Joint Biosimilar Business
June 24, 2013
- Toho Holdings Targets 26.1 Billion Yen Operating Profit in FY2015
June 24, 2013
- Volibris Receives Orphan Drug Designation for Indication of CTEPH in Japan: GSK
June 24, 2013
- Kowa, Sanofi File NDAs for SGLT-2 Inhibitor Tofogliflozin in Japan
June 24, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…